Press Release Source: CytoGenix Inc.
CytoGenix Inc. and The University of Texas M. D. Anderson Cancer Center Form Collaboration for Melanoma Gene Target Validation
Tuesday November 26, 9:30 am ET
HOUSTON--(BUSINESS WIRE)--Nov. 26, 2002--CytoGenix Inc. (OTCBB:CYGX - News) announced today it has formed a scientific collaboration with Dr. Madeleine Duvic, Professor of Internal Medicine and Dermatology, Division of Internal Medicine and Deputy Chair of Dermatology, The University of Texas M. D. Anderson Cancer Center in Houston, to investigate, test and evaluate a gene believed to be related to melanoma.
Building on Dr. Duvic's team's research CytoGenix' scientific team will be using the company's proprietary ssDNA Expression System to construct and deliver target-specific gene knockout sequences to melanoma cancer cells. This work could form the basis for further research into better treatments for this difficult-to-treat disease. The American Cancer Society estimates that about 53,600 new melanomas will be diagnosed in the United States during 2002 and 7,400 people are expected to die.
Dr. Malcolm Skolnick, CytoGenix' President and CEO, goes on to say, "We are very pleased to be working with Dr. Duvic and with M. D. Anderson, the best cancer hospital in the country. Our ssDNA technology is being used quite effectively by cancer researchers in other institutions to knock out genes related to prostate and to breast cancer. Melanoma is especially lethal because of its propensity to rapidly metastasize, and any possible treatment would certainly save many lives."
Dr. Duvic is Associate Medical Director of the Melanoma and Skin Center at M.D. Anderson Cancer Center. She is board certified in internal medicine and dermatology and her research interests include molecular biology and the pathogenesis of CTCL, sezary syndrome and skin cancers. Dr. Duvic received her M.D. from Duke University Medical School.
CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued US patent and 36 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.
--------------------------------------------------------------------------------
Contact:
CytoGenix Inc., Houston
Maury Fogle, 281/988-6118
biz.yahoo.com |
